Observational Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Oct 10, 2018; 7(6): 123-128
Published online Oct 10, 2018. doi: 10.5527/wjn.v7.i6.123
Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide
Aristeidis Stavroulopoulos, Vasiliki Aresti, Christoforos Papadopoulos, Panagiotis Nennes, Polixeni Metaxaki, Anastasios Galinas
Aristeidis Stavroulopoulos, Vasiliki Aresti, Christoforos Papadopoulos, Panagiotis Nennes, Polixeni Metaxaki, Anastasios Galinas, Department of Nephrology, IASIO Hospital, General Clinic of Kallithea, Athens 17676, Greece
Author contributions: All of the authors contributed to the study design; Stavroulopoulos A, Aresti V and Papadopoulos C collected the data; Stavroulopoulos A analyzed the data and drafted the manuscript; all authors contributed to the conception of the paper, interpretation of data, and subsequent revisions of the manuscript.
Institutional review board statement: The protocol for the research project has been approved by the IASIO Hospital’s Ethics Committee and conforms to the provisions of the Declaration of Helsinki.
Informed consent statement: Informed written consent was obtained from all patients before they entered the study.
Conflict-of-interest statement: None to declare.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Aristeidis Stavroulopoulos, BM BCh, MD, Chief Doctor, Doctor, Department of Nephrology, IASIO Hospital, General Clinic of Kallithea, Sivitanidou 36, Athens 17676, Greece. stavoulopoulos@yahoo.co.uk
Telephone: +30-69-47824197 Fax: +30-21-09583722
Received: June 4, 2018
Peer-review started: June 4, 2018
First decision: July 11, 2018
Revised: August 2, 2018
Accepted: August 30, 2018
Article in press: August 30, 2018
Published online: October 10, 2018
Processing time: 128 Days and 13.1 Hours
ARTICLE HIGHLIGHTS
Research background

The effect of phosphate binders in clinically important outcomes, such as metabolic acidosis, remains understudied.

Research motivation

There are no studies examining the effect of the novel phosphate binder sucroferric oxyhydroxide (SFOH) on acid-base status.

Research objectives

Examine possible alterations in acid-base parameters in hemodialysis patients switching from lanthanum carbonate (LanC) to SFOH.

Research methods

Fifteen stable hemodialysis patients switched from LanC to SFOH. We compared pre- and post-switching blood gas analyses, whilst hemodialysis conditions and medications remained stable.

Research results

Switching from LanC to the novel phosphate binder SFOH did not have any significant effect on blood bicarbonate levels and gas analysis. No correlations were found, either between pre-switching LanC daily dose or between post-switching daily dose of the new binder and the measured parameters.

Research conclusions

This is the first study that evaluates acid-base status in patients switching from LanC to the new phosphate binder SFOH, showing that there is no need to change hemodialysis prescription regarding these parameters.

Research perspectives

Our study can serve as a pilot for further studies with a larger number of patients, different binders and extended durations, to better understand their effect in clinically important outcomes, such as metabolic acidosis.